



Thomas Weisel Partners Healthcare Conference to Webcast Alkermes' Corporate Presentation

August 31, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 31, 2006--Alkermes, Inc. (Nasdaq: ALKS) announced today that its corporate update will be webcast live by Thomas Weisel on Friday, September 8, 2006 at 8:00 a.m. EDT. The presentation will be webcast from The Four Seasons Hotel in Boston and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a biotechnology company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company has two commercial products. RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, is marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson. VIVITROL(R) (naltrexone for extended-release injectable suspension) is the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and is marketed in the United States primarily by Cephalon, Inc. The Company has a pipeline of extended-release injectable products and pulmonary products based on its proprietary technology and expertise. Alkermes' product development strategy is twofold: the Company partners its proprietary technology systems and drug delivery expertise with several of the world's finest pharmaceutical companies; and it also develops novel, proprietary drug candidates for its own account. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

VIVITROL(R) is a registered trademark of Cephalon, Inc. and RISPERDAL(R) CONSTA(R) is a registered trademark of Johnson & Johnson Corporation.

CONTACT: Alkermes, Inc. Debra Koufos, 617-583-6220 Associate, Corporate Communications SOURCE: Alkermes, Inc.